Carcinoembryonic antigen (CEA) testing in colorectal cancer follow up: what do patients think?
AUTOR(ES)
Steele, Nicola
FONTE
BMJ Group
RESUMO
The carcinoembryonic antigen (CEA) blood test is included in most colorectal cancer follow up protocols, despite little clear evidence for its cost‐effectiveness and survival benefit. In this study, patients' views were sought on the use of the CEA blood test in their follow up. Strong associations were found between the age of a patient's children and their concern about cancer recurrence and between concern about recurrence and anxiety about CEA test results (p<0.0001). Many patients expressed a desire for prognostic information, however uncertain or poor. Patients' views should be sought when designing colorectal cancer follow up protocols to ensure their needs are adequately addressed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2600007Documentos Relacionados
- Raised carcinoembryonic antigen level as an indicator of recurrent disease in follow up of patients with colorectal cancer.
- Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry.
- Brugada Pattern, Brugada Phenocopy, What to Think?
- Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers
- Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients- is it important?
